Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

G. V. Long; A. Hauschild; M. Santinami; V. G. Atkinson; M. Mandala; V. Chiarion-Sileni; J. Larkin; C. Robert; D. Schadendorf; K. Dasgupta; M. Shilkrut; J. Garrett; J. C. Brase; R. Kefford; J. M. Kirkwood; R. Dummer

doi:10.1093/annonc/mdy424.053

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

G. V. Long, A. Hauschild, M. Santinami, V. G. Atkinson, M. Mandala, V. Chiarion-Sileni, J. Larkin, C. Robert, D. Schadendorf, K. Dasgupta, M. Shilkrut, J. Garrett, J. C. Brase, R. Kefford, J. M. Kirkwood, R. Dummer

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	LBA43
Pages (from-to)	viii734-viii735
Number of pages	2
Journal	Annals of Oncology
Volume	29
Issue number	Supplement 8
DOIs	https://doi.org/10.1093/annonc/mdy424.053
Publication status	Published - 1 Oct 2018
Event	43rd European Society for Medical Oncology Congress (ESMO 2018) - Munich, Germany Duration: 19 Oct 2018 → 23 Oct 2018

Access to Document

10.1093/annonc/mdy424.053

Cite this

Long, G. V., Hauschild, A., Santinami, M., Atkinson, V. G., Mandala, M., Chiarion-Sileni, V., Larkin, J., Robert, C., Schadendorf, D., Dasgupta, K., Shilkrut, M., Garrett, J., Brase, J. C., Kefford, R., Kirkwood, J. M., & Dummer, R. (2018). Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. Annals of Oncology, 29(Supplement 8), viii734-viii735. [LBA43]. https://doi.org/10.1093/annonc/mdy424.053

@article{f21f2a9886f04c7199ac1bcad6d9b117,

title = "Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma",

author = "Long, {G. V.} and A. Hauschild and M. Santinami and Atkinson, {V. G.} and M. Mandala and V. Chiarion-Sileni and J. Larkin and C. Robert and D. Schadendorf and K. Dasgupta and M. Shilkrut and J. Garrett and Brase, {J. C.} and R. Kefford and Kirkwood, {J. M.} and R. Dummer",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy424.053",

language = "English",

volume = "29",

pages = "viii734--viii735",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "OXFORD UNIV PRESS INC",

number = "Supplement 8",

note = "43rd European Society for Medical Oncology Congress (ESMO 2018) ; Conference date: 19-10-2018 Through 23-10-2018",

}

Long, GV, Hauschild, A, Santinami, M, Atkinson, VG, Mandala, M, Chiarion-Sileni, V, Larkin, J, Robert, C, Schadendorf, D, Dasgupta, K, Shilkrut, M, Garrett, J, Brase, JC, Kefford, R, Kirkwood, JM & Dummer, R 2018, 'Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma', Annals of Oncology, vol. 29, no. Supplement 8, LBA43, pp. viii734-viii735. https://doi.org/10.1093/annonc/mdy424.053

Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. / Long, G. V.; Hauschild, A.; Santinami, M. et al.
In: Annals of Oncology, Vol. 29, No. Supplement 8, LBA43, 01.10.2018, p. viii734-viii735.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma

AU - Long, G. V.

AU - Hauschild, A.

AU - Santinami, M.

AU - Atkinson, V. G.

AU - Mandala, M.

AU - Chiarion-Sileni, V.

AU - Larkin, J.

AU - Robert, C.

AU - Schadendorf, D.

AU - Dasgupta, K.

AU - Shilkrut, M.

AU - Garrett, J.

AU - Brase, J. C.

AU - Kefford, R.

AU - Kirkwood, J. M.

AU - Dummer, R.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy424.053

DO - 10.1093/annonc/mdy424.053

M3 - Article

C2 - 32138017

SN - 0923-7534

VL - 29

SP - viii734-viii735

JO - Annals of Oncology

JF - Annals of Oncology

IS - Supplement 8

M1 - LBA43

T2 - 43rd European Society for Medical Oncology Congress (ESMO 2018)

Y2 - 19 October 2018 through 23 October 2018

ER -

Long GV, Hauschild A, Santinami M, Atkinson VG, Mandala M, Chiarion-Sileni V et al. Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. Annals of Oncology. 2018 Oct 1;29(Supplement 8):viii734-viii735. LBA43. doi: 10.1093/annonc/mdy424.053